(Q38151453)

29 August 2017

title

Weight considerations in psychotropic drug prescribing and switching (English)

1 reference

29 August 2017

Mehrul Hasnain

1

1 reference

29 August 2017

W Victor R Vieweg

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 September 2013

1 reference

29 August 2017

published in

Postgraduate Medicine

1 reference

29 August 2017

volume

125

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

117-129

1 reference

Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Psychotropic drug considerations in depressed patients with metabolic disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Weight effects associated with antipsychotics: a comprehensive database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Understanding the burden of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Asenapine: a clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Weight gain associated with neuroleptic medication: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Antipsychotic drugs for first-episode schizophrenia: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

A case series: evaluation of the metabolic safety of aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Treatment of morbidly obese psychotic patients with molindone: three case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Datapoints: psychotropic drug prescriptions by medical specialty

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Antidepressants and Body Weight

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Review of the side-effect profile of buspirone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Effects of Nefazodone on Body Weight

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Bupropion: a review of its use in the management of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Anxiety disorders: a comprehensive review of pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Valproate, weight gain and carbohydrate craving: a gender study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Ramelteon attenuates age-associated hypertension and weight gain in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Association between adult attention deficit/hyperactivity disorder and obesity in the US population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Naltrexone for the treatment of obesity: review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Weight gain in smokers after quitting cigarettes: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

A Double-blind, Placebo-Controlled, Randomized Trial of Bupropion for Smoking Cessation in Primary Care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2706

21 January 2018

Identifiers

DOI

10.3810/PGM.2013.09.2706

1 reference

29 August 2017

1 reference